Impact of HIV and recreational drugs on cognitive functions in young men having sex with men - Henrard, Sophie; Trotta, Nicola; Rovai, Antonin; Coolen, Tim; Slama, Hichem; Bertels, Julie; Puttaert, Delphine; Goffard, Jean-Christophe; Van Vooren, Jean-Paul; Goldman, Serge; De Tiège, Xavier (medRxiv, 2022)
Objectives This study characterizes the structural and metabolic cerebral correlates of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) in a preclinical setting that considers the lifestyle of young European men exposed to HIV, including recreational drugs.Design Prospective inclusion of participants.Methods Simultaneous structural brain magnetic resonance imaging (MRI) and positron emission tomography using [18F]-fluorodeoxyglucose (FDG-PET) were acquired on a hybrid PET-MRI system in 23 asymptomatic young men with HIV+ (mean age: 33.6 years, age range: 23-60 years; normal CD4+ cell count, undetectable viral load). Neuroimaging data were compared with that of a group of 26 young HIV-men, highly well matched for what concerns age, lifestyle, named pre-exposure prophylaxis users (HIV-PrEP), and to a group of 23 undifferentiated matched young men (i.e., healthy controls). A comprehensive neuropsychological assessment was also administered to the HIV+ and HIV-PrEP subjects.Results HIV+ subjects had lower performances in executive, attentional and working memory functions compared to HIV-PrEP subjects. No structural or metabolic differences were found between those two groups. Compared to healthy controls, HIV+ and HIV-PrEP exhibited a common frontal hypometabolism in the right prefrontal cortex that correlated with the level of recreational drug use. No structural brain abnormality was found.Conclusion A dynamic prevention of recreational drugs use in HIV+ and HIV-PrEP subjects is mandatory to cope with their negative impact on brain function and their neurocognitive consequences. A complex interplay between recreational drugs and HIV might be involved in the development of neurocognitive disorders in young men with HIV.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSophie Henrard and Delphine Puttaert have been supported by the Fonds Erasme (Brussels, Belgium). Tim Coolen has been a Clinical Master Specialist applicant to a PhD at the Fonds de la Recherche Scientifique (FRS-FNRS, Brussels, Belgium). Xavier De Tiege is Clinical Researcher at the FRS-FNRS. The PET-MR project at the ULB has been supported by the Association Vincotte Nuclear (Brussels, Belgium). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants contributed to the study approved by the institutional Ethics Committee after written informed consent. Ethics Committee Erasme Hospital (808 route de Lennik 1070 Brussels, Belgium)gave its agreement on 11/12/2017. Board members: Pr J-M Boeynaems, biologist, MD, PhD, Pr S Goldman, Neurologist, MD, PhD, Pr H Louis, gastroenterologist, MD, PhD, Mrs Benammar, Hospital pharmacist, Mr A Counet, Economist, Dr E Demanet, General practitioner, MD, Mrs Didens, Nurse, Pr I Langer, pharmacologist, PharmaD, PhD, Dr V Lesage, Geriatist, MD, Pr G Loas, psychiatrist, MD, PhD, Mr M Mayer, Moral Counsel, BSc, PhD, Mme A Petiau, psychologist, Pr F Roufosse, internist MD, PhD, Mme C Sauvage, Physiotherapist, BSc, PhD and Pr J-L Vachiery, cardiologist, MD. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors